Tyra-300-B01

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

4 Countries

Phase II

Phase I (FiH)

Phase II: 2 Phase I (FiH): 1

Oversight events:

3 temporary halts across 1 trial

View oversight register →

Sponsors using this IMP

Tyra Biosciences Inc. 3

All trials

3 total

A study to investigate dabogratinib (TYRA-300) in participants with Low Grade Upper Tract Urothelial Carcinoma Pending

2025-523539-20-00 Phase II 3 countries Tyra Biosciences Inc.
A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer Recruiting

2025-521277-14-00 Phase II 3 countries Tyra Biosciences Inc.
A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors Ended

2023-507589-22-00 Phase I (FiH) 3 countries Tyra Biosciences Inc.

Showing 1–3 of 3 trials

← All drugs A–Z